secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition Corp. (DMAA)
CIK:        0002028614
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001213900-26-048585
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DMAA updates CFO equity to 175k shares, sets CEO compensation terms, both tied to definitive deal
--------------------------------------------------------------------------------

- CFO Saleem Elmasri's share grant increased from 100k to 175k ordinary shares, earned upon signing a definitive agreement and issued at closing of initial business combination.
- CEO Roger Bendelac receives 250k ordinary shares under same vesting trigger; monthly cash comp of $4,500 with up to $2,000 deferrable based on cash flow.
- Monthly CFO fee unchanged at $3,500; unpaid amounts accrue as binding obligations; shares replace prior unissued 100k.
- Compensation structures signal progress toward a business combination, though no definitive agreement announced as of April 28, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026048585/0001213900-26-048585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026048585/ea0287918-8k_drugs.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-048585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer